KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenet Healthcare (THC) Gains from Sales and Divestitures (2016 - 2017)

Tenet Healthcare's Gains from Sales and Divestitures history spans 9 years, with the latest figure at $960836.0 for Q1 2017.

  • For Q1 2017, Gains from Sales and Divestitures fell 21.44% year-over-year to $960836.0; the TTM value through Mar 2017 reached $960836.0, down 21.44%, while the annual FY2016 figure was $1.6 million, 35.9% up from the prior year.
  • Gains from Sales and Divestitures for Q1 2017 was $960836.0 at Tenet Healthcare, down from $1.6 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.6 million in Q4 2016 and bottomed at $839353.0 in Q1 2014.
  • The 5-year median for Gains from Sales and Divestitures is $996363.0 (2015), against an average of $1.1 million.
  • The largest annual shift saw Gains from Sales and Divestitures plummeted 76.04% in 2013 before it surged 41.41% in 2016.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $966838.0 in 2013, then increased by 4.46% to $1.0 million in 2014, then increased by 19.83% to $1.2 million in 2015, then soared by 35.9% to $1.6 million in 2016, then tumbled by 41.58% to $960836.0 in 2017.
  • Per Business Quant, the three most recent readings for THC's Gains from Sales and Divestitures are $960836.0 (Q1 2017), $1.6 million (Q4 2016), and $1.5 million (Q3 2016).